Innovation for Health - 13 February 2020
Contact Investor Forum I4H Bootcamp
LinkedIn
Twitter
Facebook
Innovation for Health - Shaping the future of healthcare

Luc Sterkman

CEO, Caelus Health

Session

14:45 - 15:35
Biotech breakthroughs

Luc Sterkman, MD (CEO) obtained his medical degree (MD) in 1988 at the Free University in Amsterdam. He has broad experience in the fields of general management, business development and R&D. From 1992-2002 he was COO and later CEO of U-Gene Research, that was successfully sold to Kendle USA (NASDAQ –KNDL). From 2002 to 2004, he worked as a Board member of the biotech company OctoPlus and from 2005 to 2010 he was General manager at the pharmaceutical company Disphar International BV (part of the Nordic Group). From 2011-2016 he worked as a COO at Newtricious, which company is focusing on innovative nutrition and functional foods. As the CEO at Caelus Health, he is since January 2016 overall responsible for building and directing the company in the next phase of growth and further expanding its pipeline of new microbiota-based products in the field of cardio-metabolic diseases.

Abstract

Microbiome-based therapeutics; a new rapidly growing field
Gut microorganisms, referred to as microbiota or microbiome, represent a broad and rapidly growing basis for new products and therapies based on individual microbiota or consortia of microorganisms and /or their metabolites. These products and therapies could help prevent or treat not only gastrointestinal disorders, but also address diseases in many clinical fields including oncology, dermatology, immunology and cardiovascular disorders.

Caelus Health is a company based on technologies of the Academic Medical Centre in Amsterdam and Wageningen University. The company is dedicated to developing microbiome-based therapeutics in cardio-metabolic disorders with an initial focus on Diabetes. Caelus has secured financial support from the Johnson & Johnson Development Corporation and performs its preclinical R&D at the well-established JLABS @ BE incubator and labs on the Janssen R&D campus in Beerse. Its first product is in Phase 2 clinical trials.
Michel Dumontier
Maastricht University
Thijn Brummelkamp
Scenic Biotech
Hans Schikan
Topsector Life Sciences & Health
Inge Huitinga
The Netherlands Brain Bank
Sjaak Vink
TheSocialMedwork
Annemarie Jorritsma
NVP
Wiro Niessen
Erasmus MC, TU Delft & Quantib
Tim Knotnerus
AgomAb Therapeutics
Elise Meijer
Antwerp Management School & Accenture Strategy
Esther Talboom-Kamp
Saltro Diagnostics
Joep Muijrers
PureTech Health
Els Beirnaert
Aelin Therapeutics
Carine van den Brink
Axon Lawyers

Claudia Rijcken
pharmi

Rajiv Vaid Basaiawmoit
Aarhus University & Biosymfonix
Sponsors & Partners 2020
Host sponsor
Erasmus MC
Host sponsor
Gemeente Rotterdam
Host sponsor
Life Sciences & Health 010
Platinum sponsor
Gold sponsor
Award sponsor
AXON Lawyers
Media sponsor
Powered by
Hyphen Projects
© 2019 Innovation for Health
Hyphen Projects uses cookies to remember certain preferences.